Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer

References

• Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241. doi: 10.1016/j.eururo.2012.07.033
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Compérat EM, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76(5):639–657. doi: 10.1016/j.eururo.2019.08.016
   PubMed Web of Science ®Google Scholar
• Kakiashvili DM, van Rhijn BW, Trottier G, et al. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-guérin treatment. BJU Int. 2011;107(4):540–546. doi: 10.1111/j.1464-410X.2010.09572.x
   PubMed Web of Science ®Google Scholar
• Taylor J, Becher E, Steinberg GD. Update on the guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2020;125(2):197–205. doi: 10.1111/bju.14915
   PubMed Web of Science ®Google Scholar
• Chehroudi AC, Black PC. Emerging intravesical therapies for the management of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer: charting a path forward. Can Urol Assoc J. 2020 Jun;14(6):204–213. doi: 10.5489/cuaj.6101
   PubMed Web of Science ®Google Scholar
• Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016;34(16):1935–1944. doi: 10.1200/JCO.2015.64.4070
   PubMed Web of Science ®Google Scholar
• Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–1029. doi: 10.1016/j.juro.2016.06.049
   PubMed Web of Science ®Google Scholar
• Flaig TW, Spiess PE, Abern M, et al. NCCN guidelines® insights: bladder cancer, version 2.2022. J Natl Compr Canc Netw. 2022;20(8):866–878. doi: 10.6004/jnccn.2022.0041
   PubMed Web of Science ®Google Scholar
• Roumiguié M, Kamat AM, Bivalacqua TJ, et al. International bladder cancer group consensus statement on clinical trial design for patients with bacillus Calmette-Guérin-exposed high-risk non-muscle-invasive bladder cancer. Eur Urol. 2022;82(1):34–46. doi: 10.1016/j.eururo.2021.12.005
   PubMed Web of Science ®Google Scholar
• Kim HS, Seo HK. Emerging treatments for bacillus Calmette-guérin-unresponsive non-muscle-invasive bladder cancer. Investig Clin Urol. 2021;62(4):361–377. doi: 10.4111/icu.20200602
   PubMed Web of Science ®Google Scholar
• Nazmifar M, Williams C, Naser-Tavakolian A, et al. Clinical and preclinical therapies for bladder cancer following bacillus Calmette-guérin failure. J Urol. 2023;209(1):32–48. doi: 10.1097/JU.0000000000002957
   PubMed Web of Science ®Google Scholar
• Maffezzini M, Campodonico F, Canepa G, et al. Short-schedule intravesical gemcitabine with ablative intent in recurrent ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder. Eur Urol. 2007;51(4):956–961. doi: 10.1016/j.eururo.2006.08.038
   PubMed Web of Science ®Google Scholar
• Campodonico F, Canepa G, Capponi G, et al. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. Anticancer Res. 2005;25(3c):2381–2384.
   PubMed Web of Science ®Google Scholar
• Bassi P, De Marco V, Tavolini IM, et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy. Urol Int. 2005;75(4):309–313. doi: 10.1159/000089164
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002;20(15):3193–3198. doi: 10.1200/JCO.2002.02.066
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24(18):2729–2734. doi: 10.1200/JCO.2005.05.2720
   PubMed Web of Science ®Google Scholar
• Mohanty NK, Nayak RL, Vasudeva P, et al. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol. 2008;26(6):616–619. doi: 10.1016/j.urolonc.2007.10.016
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus bacille Calmette-guérin after initial bacille Calmette-guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010;116(8):1893–1900. doi: 10.1002/cncr.24914
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28(4):543–548. doi: 10.1200/JCO.2008.20.8199
   PubMed Web of Science ®Google Scholar
• Sternberg IA, Dalbagni G, Chen LY, et al. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-guérin treatment failure. J Urol. 2013;190(5):1686–1691. doi: 10.1016/j.juro.2013.04.120
   PubMed Web of Science ®Google Scholar
• Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-guérin. J Urol. 2013;190(4):1200–1204. doi: 10.1016/j.juro.2013.04.031
   PubMed Web of Science ®Google Scholar
• Porena M, Del Zingaro M, Lazzeri M, et al. Bacillus Calmette-guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int. 2010;84(1):23–27. doi: 10.1159/000273461
   PubMed Web of Science ®Google Scholar
• Gacci M, Bartoletti R, Cai T, et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int. 2006;76(2):106–111. doi: 10.1159/000090870
   PubMed Web of Science ®Google Scholar
• Perdonà S, Di Lorenzo G, Cantiello F, et al. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs. 2010;21(1):101–106. doi: 10.1097/CAD.0b013e3283324d83
   PubMed Web of Science ®Google Scholar
• Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology. 2005;66(4):726–731. doi: 10.1016/j.urology.2005.04.062
   PubMed Web of Science ®Google Scholar
• Gunelli R, Bercovich E, Nanni O, et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer. 2007;97(11):1499–1504. doi: 10.1038/sj.bjc.6604074
   PubMed Web of Science ®Google Scholar
• Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology. 2005;65(1):65–69. doi: 10.1016/j.urology.2004.08.027
   PubMed Web of Science ®Google Scholar
• Gontero P, Oderda M, Mehnert A, et al. The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol. 2013;190(3):857–862. doi: 10.1016/j.juro.2013.03.097
   PubMed Web of Science ®Google Scholar
• Mattioli F, Curotto A, Manfredi V, et al. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. Anticancer Res. 2005;25(3c):2493–2496.
   PubMed Web of Science ®Google Scholar
• Gontero P, Casetta G, Maso G, et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol. 2004;46(3):339–343. doi: 10.1016/j.eururo.2004.05.001
   PubMed Web of Science ®Google Scholar
• Hurle R, Contieri R, Casale P, et al. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure. Urol Oncol. 2021;39(3):.e195.7–.e195.13. doi: 10.1016/j.urolonc.2020.09.017
   Web of Science ®Google Scholar
• Prasanna T, Craft P, Balasingam G, et al. Intravesical gemcitabine versus intravesical bacillus Calmette-guérin for the treatment of non-muscle invasive bladder cancer: an evaluation of efficacy and toxicity. Front Oncol. 2017;7:260. doi: 10.3389/fonc.2017.00260
   PubMed Web of Science ®Google Scholar
• Ansari Djafari A, Javanmard B, Razzaghi M, et al. Intravesical gemcitabine versus intravesical bacillus Calmette-Guerin for the treatment of intermediate-risk non-muscle invasive bladder cancer: a randomized controlled trial. Urol J. 2023;20(2):123–128. doi: 10.22037/uj.v19i.7194
   PubMedGoogle Scholar
• Bendary L, Khalil S, Shahin A, et al. Intravesical gemcitabine versus Bacillus Calmette-Guerin (BCG) in treatment of non-muscle invasive bladder cancer: short term comparative study. J Urol. 1655;185(4):e664–e665. doi: 10.1016/j.juro.2011.02.1765
   Google Scholar
• Musat MG, Kwon CS, Masters E, et al. Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in Real-World evidence (RWE) studies: Systematic literature review (SLR). Clinicoecon Outcomes Res. 2022 Jan 10;14:35–48. doi: 10.2147/CEOR.S341896
   PubMed Web of Science ®Google Scholar
• Tully KH, Cole AP, Krimphove MJ, et al. Contemporary treatment patterns for non-muscle-invasive bladder cancer: has the use of radical cystectomy changed in the BCG shortage era? Urology. 2021;147:199–204. doi: 10.1016/j.urology.2020.08.004
   PubMed Web of Science ®Google Scholar
• Haas CR, Barlow LJ, Badalato GM, et al. The timing of radical cystectomy for bacillus Calmette-Guérin failure: comparison of outcomes and risk factors for prognosis. J Urol. 2016;195(6):1704–1709. doi: 10.1016/j.juro.2016.01.087
   PubMed Web of Science ®Google Scholar
• Anderson CB, Chen L, Chang SS, et al. Intravesical therapy compared to radical cystectomy among patients with non-muscle invasive bladder cancer requiring additional treatment after induction BCG. Clin Genitourin Cancer. 2022;20(6):595–603. doi: 10.1016/j.clgc.2022.07.001
   PubMed Web of Science ®Google Scholar
• Douglass L, Schoenberg M. The future of intravesical drug delivery for non-muscle invasive bladder cancer. Bladder Cancer. 2016;2(3):285–292. doi: 10.3233/BLC-160056
   PubMedGoogle Scholar
• Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001;93(8):597–604. doi: 10.1093/jnci/93.8.597
   PubMed Web of Science ®Google Scholar
• Toschi L, Finocchiaro G, Bartolini S, et al. Role of gemcitabine in cancer therapy. Future Oncol. 2005;1(1):7–17. doi: 10.1517/14796694.1.1.7
   PubMedGoogle Scholar
• Tonato M, Mosconi AM, Martin C. Safety profile of gemcitabine. Anticancer Drugs. 1995;6 Suppl 6:27–32. doi: 10.1097/00001813-199512006-00005
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Thomas LJ, O’Donnell MA, et al. Sequential intravesical gemcitabine and Docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer. 2015;1(1):65–72. doi: 10.3233/BLC-150008
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Packiam VT, Thomas LJ, et al. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol. 2022;40(1):e91–e97. doi: 10.1016/j.urolonc.2021.03.024
   Web of Science ®Google Scholar
• Chevuru PT, McElree IM, Mott SL, et al. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urol Oncol. 2023;41(3):e1481–e1487. doi: 10.1016/j.urolonc.2022.10.030
   Web of Science ®Google Scholar
• Pareek T, Parmar K, Sharma AP, et al. Quality of life, efficacy, and safety of sequential intravesical gemcitabine + docetaxel versus BCG for non-muscle invasive urinary bladder cancer: a pilot study. Urol Int. 2022;106(8):784–790. doi: 10.1159/000524098
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and Docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol. 2020;203(5):902–909. doi: 10.1097/JU.0000000000000688
   PubMed Web of Science ®Google Scholar
• McElree IM, Steinberg RL, Martin AC, et al. Sequential intravesical gemcitabine and Docetaxel for bacillus Calmette-Guérin-naïve high-risk nonmuscle-invasive bladder cancer. J Urol. 2022;208(3):589–599. doi: 10.1097/JU.0000000000002740
   PubMed Web of Science ®Google Scholar
• Babajide R, Labbate C, Saoud R, et al. Early experience with intravesical gemcitabine-docetaxel for BCG-Naïve patients with high grade non-muscle invasive bladder cancer. Urol Oncol. 2020;38(12):901. doi: 10.1016/j.urolonc.2020.10.038
   Web of Science ®Google Scholar
• Milbar N, Kates M, Chappidi MR, et al. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer. 2017;3(4):293–303. doi: 10.3233/BLC-170126
   PubMed Web of Science ®Google Scholar
• Malmström PU, Wijkström H, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian bladder cancer study group. J Urol. 1999;161(4):1124–1127. doi: 10.1016/S0022-5347(01)61607-0
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–918. doi: 10.1111/j.1464-410X.2010.09654.x
   PubMed Web of Science ®Google Scholar
• Hu X, Li G, Wu S. Advances in diagnosis and therapy for bladder cancer. Cancers (Basel). 2022 Jun 29;14(13):3181. doi: 10.3390/cancers14133181
   PubMed Web of Science ®Google Scholar
• Tholomier C, Martini A, Mokkapati S, et al. The current status of gene therapy in bladder cancer. Expert Rev Anticancer Ther. 2023;23(5):531–543. doi: 10.1080/14737140.2023.2203385
   PubMedGoogle Scholar
• Rubio-Briones J, Algaba F, Gallardo E, et al. Recent advances in the management of patients with non-muscle-invasive bladder cancer using a multidisciplinary approach: practical recommendations from the Spanish Oncology genitourinary (SOGUG) working group. Cancers (Basel). 2021;13(19):4762. doi: 10.3390/cancers13194762
   PubMed Web of Science ®Google Scholar